ESMO Helps Hematologists Assess New Cancer Drugs

The European Society for Medical Oncology has released a tool to help hematologists evaluate the magnitude of clinical benefit expected from new blood cancer treatments.

Related Keywords

,European Hematology Association ,World Health Organization ,European Society For Medical Oncology ,European Society ,Medical Oncology ,Medical Oncology Magnitude ,Clinical Benefit Scale ,Biologic Therapy ,Leukemia ,Cancer ,Alignant Neoplasia ,Arcinoma ,Toxicology ,Blood ,Europe ,European ,Oncological Medicine ,Tumor ,Clinical Guidelines ,Guidelines ,Hematology ,Non Hodgkins Lymphoma ,Follicular Lymphoma ,Chimeric Antigen Receptort Cell Therapy ,Chimeric Antigen Receptors ,Himeric Immunoreceptors ,Himerict Cell Receptors ,Rtificialt Cell Receptors ,Ar T ,Hematologic Malignancies ,Polym ,